Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS [NYSE]
Novartis AG
Index- P/E23.11 EPS (ttm)4.33 Insider Own- Shs Outstand2.70B Perf Week-2.84%
Market Cap270.49B Forward P/E18.02 EPS next Y5.55 Insider Trans- Shs Float460.99M Perf Month0.92%
Income10.66B PEG2.82 EPS next Q1.07 Inst Own9.90% Short Float0.54% Perf Quarter4.72%
Sales53.63B P/S5.04 EPS this Y16.20% Inst Trans-0.04% Short Ratio1.27 Perf Half Y11.52%
Book/sh29.39 P/B3.40 EPS next Y6.56% ROA10.50% Target Price103.57 Perf Year20.31%
Cash/sh5.00 P/C20.03 EPS next 5Y8.20% ROE18.60% 52W Range80.64 - 103.50 Perf YTD8.00%
Dividend2.82 P/FCF73.44 EPS past 5Y3.20% ROI10.50% 52W High-3.31% Beta0.48
Dividend %2.82% Quick Ratio1.20 Sales past 5Y3.50% Gross Margin67.70% 52W Low24.09% ATR1.52
Employees133413 Current Ratio1.40 Sales Q/Q-2.00% Oper. Margin22.70% RSI (14)49.21 Volatility0.88% 1.08%
OptionableYes Debt/Eq0.29 EPS Q/Q23.50% Profit Margin24.50% Rel Volume0.52 Prev Close102.40
ShortableYes LT Debt/Eq0.19 Earnings- Payout50.90% Avg Volume1.96M Price100.07
Recom1.80 SMA20-1.00% SMA502.39% SMA2008.06% Volume1,018,892 Change-2.28%
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Apr-02-07Reiterated Banc of America Sec Buy $66 → $65
Mar-02-15 10:20AM  5 Dividend Stocks to Buy as European Index Crushes S&P 500 at 24/7 Wall St.
10:05AM  Elliott Management adds new position in Allergan Market Realist
07:50AM  Early movers: BRK.B, AAPL, LL, CAH, BSX & more at CNBC
Feb-27-15 04:15PM  Interested In Pharmaceutical Stocks? Try Novartis (ADR) at Investopedia
11:30AM  Novartis treatment for vision loss meets goals in study Reuters
10:14AM  Novartis Japan Ordered to Shut Down 15 Days at The Wall Street Journal
09:10AM  Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin at Forbes
08:20AM  You Need to Know About This Healthcare ETF ETF Trends
07:00AM  Compelling Financial Benefit in Valeant's Latest Buy Morningstar
12:27AM  Novartis Amends Heart-Drug Trial at The Wall Street Journal
Feb-26-15 06:36PM  Novartis Amends Heart-Drug Trial at The Wall Street Journal
02:53PM  What You Should Know Before Watching Vice's Special About Curing Cancer at Forbes
09:30AM  Familiar ETF Friend Will Enjoy a Pharmacyclics Sale ETF Trends
09:05AM  Exchange-traded funds that hold big pharma Market Realist
09:00AM  Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Zacks
Feb-25-15 02:32PM  Pharmacyclics mulls sale; J&J, Novartis interested - Bloomberg Reuters
01:15PM  GSK to be No. 1 vaccine producer when it completes $25B asset swap with Novartis next week at American City Business Journals
11:47AM  GSK set to complete $20 billion Novartis asset swap next week Reuters
11:42AM  GSK set to complete $20 bln Novartis asset swap next week Reuters
11:21AM  Investors pay to lend Germany money now at CNNMoney.com
Feb-24-15 05:06PM  Big pharma diversifies business to mitigate patent risk Market Realist
04:13PM  Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog Zacks
02:27PM  Brain-Altering Devices May Supplant Drugs -- And Pharma Is OK With That at Forbes
12:56PM  In The Book Of Life, A Second Map Is Opened at Forbes
12:56PM  In The Book Of Life, A Second Map Is Established at Forbes
10:04AM  United Therapeutics Blood Pressure Drug Lifts Q4 at Investor's Business Daily
Feb-23-15 04:49PM  Hot Income Stocks: Who's Growing Dividends The Fastest? at Investor's Business Daily
03:58PM  FDA approves Novartis drug for bone marrow cancer AP
11:06AM  Big pharma invests big money in research and development Market Realist
Feb-18-15 09:27AM  Momenta (MNTA) Posts Wider-than-Expected Loss in Q4 - Analyst Blog Zacks
Feb-17-15 01:26PM  Can Veeva Systems' Software Keep Luring Big Pharma? at Investor's Business Daily
Feb-16-15 03:40PM  Novartis' (NVS) Cardiovascular Drug Granted Priority Review - Analyst Blog Zacks
Feb-13-15 03:32PM  Novartis, Verastem & Cepheid Making Biotech Headlines On Friday Benzinga
09:20AM  Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog Zacks
Feb-09-15 06:04PM  Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog Zacks
Feb-06-15 02:15PM  Dow 30 Stock Roundup: Disney, Exxon Beat, United Technologies Raises Dividend - Analyst Blog Zacks
Feb-05-15 06:13PM  Pfizer Xeljanz Label Expansion Application Under FDA Review - Analyst Blog Zacks
03:12PM  Very weird: Corporate bond rates go negative at CNNMoney.com
09:05AM  Glaxo Posts In Line Q4 Earnings, HIV Segment Sales Grow - Analyst Blog Zacks
Feb-04-15 06:07PM  Novartis' Alcon Receives FDA Approval for Pazeo Solution - Analyst Blog Zacks
12:30PM  Pfizer's Breast Cancer Drug Ibrance Wins Early FDA Nod - Analyst Blog Zacks
08:45AM  GSK sales falls; firm upbeat on respiratory unit at CNBC
Feb-03-15 01:04PM  NOVARTIS AG Financials EDGAR Online Financials
12:11PM  Novartis faces suspension in Japan over drug trial allegations at Financial Times
10:46AM  Novartis Unit in Japan is Threatened with a 15-Day Suspension at The Wall Street Journal
Feb-02-15 04:45PM  Will Glaxo (GSK) Q4 Earnings Suffer from Lower Revenues? - Analyst Blog Zacks
02:20PM  Around the Region: Feb. 2, 2015 at American City Business Journals
Jan-31-15 11:24AM  First Hand Account: The White House Precision Medicine Announcement at Forbes
Jan-30-15 11:39AM  Valeant Agrees To Buy Dendreon's Provenge at Investor's Business Daily
10:54AM  Eli Lilly's 4Q Earnings Beat, Revenue Outlook Lowered - Analyst Blog Zacks
10:50AM  Dr. Reddy's (RDY) Q3 Earnings Down 7% Y/Y, Revenues Up - Analyst Blog Zacks
07:45AM  Activis CEO: Innovation vs. acquisition CNBC
Jan-29-15 04:35PM  Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog Zacks
08:27AM  Roche Misses on Earnings in 2014, Beats on Revenues - Analyst Blog Zacks
Jan-28-15 01:27PM  EU Approves Novartis-Glaxo Deals at The Wall Street Journal
12:40PM  The $25B GSK-Novartis deal clears major hurdle at American City Business Journals
12:00PM  Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Zacks
10:00AM  Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog Zacks
Jan-27-15 09:02PM  Novartis AG (NVS) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
06:10PM  Drug Firms Report Good Q4, But Outlook Cloudy at Investor's Business Daily
04:15PM  Novartis (NVS) Stock Gains Today on Earnings Beat at TheStreet
11:57AM  Bristol, Pfizer, Novartis Forecasts Face FX Pressures at Investor's Business Daily
09:29AM  Novartis Upbeat Despite Weaker Profit at The Wall Street Journal
06:50AM  Banks lead Europe lower; Greek stocks down 3% at CNBC
04:33AM  Novartis looks to new drugs to fuel growth as restructuring gels at Financial Times
03:46AM  Novartis (NVS) Beats on Earnings & Revenues - Tale of the Tape Zacks
03:36AM  Swiss drug maker Novartis posts Q4 profit drop AP
01:45AM  We're looking for bolt-on acquisitions: Novartis CEO CNBC
01:45AM  Novartis CEO on euro, Swiss franc effect CNBC
01:41AM  Novartis 4Q Core EPS $1.21; Est. $1.19 at Bloomberg
01:18AM  Novartis Sees Sales Growth Resuming After Earnings Rise at Bloomberg
Jan-26-15 12:20PM  Lannett Early Q2 Earnings Beat Estimates; Stock Jumps at Investor's Business Daily
08:28AM  Senator Elizabeth Warren Has Big Pharma In Her Crosshairs -- But Her Aim Is Off at Forbes
07:00AM  Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-23-15 06:00PM  Array BioPharma shares jump on news of Novartis cancer-drug deal at American City Business Journals
05:50PM  Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog Zacks
12:02PM  Array shares jump after drugmaker details Novartis deal AP
06:30AM  The Morning Ledger: Businesses, Investors Cheer Europe's Bet on Stimulus at The Wall Street Journal
06:15AM  Up to Speed: Death of Saudi king moves needle on oil prices (Video) at American City Business Journals
Jan-22-15 05:40PM  Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Zacks
02:06PM  An easier way to understand the pharma industry Market Realist
11:24AM  Novartis CEO says reviewing Swiss costs after franc shock Reuters
10:25AM  Novartis Fourth-Quarter Profit May Drop: Earnings Preview at The Wall Street Journal
08:14AM  We are funding part of ACA: Novartis CEO CNBC
Jan-21-15 04:00PM  Teva Up on Positive Copaxone Supreme Court Ruling - Analyst Blog Zacks
01:27PM  FDA Approves Novartis Psoriasis Drug at The Wall Street Journal
12:39PM  Novartis Wins U.S. Approval for First of New Psoriasis Drugs at Bloomberg
Jan-20-15 06:03PM  Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - Analyst Blog Zacks
04:03PM  Supreme Court Hands Trial Courts More Power In Teva Patent Case at Forbes
03:10PM  New year brings change in ownership for Greensboro's Novartis Animal Health at American City Business Journals
12:49PM  Supreme Court rules against Momenta on generic Copaxone case at American City Business Journals
Jan-15-15 02:36PM  6 Stocks Riding the Swiss Franc Surge - Stocks in the News Zacks
02:12PM  3 Reasons To Be Bullish On Generic Drug Firm Akorn at Investor's Business Daily
01:42PM  Which stocks suffered on Swiss move? CNBC
01:07PM  Swiss move stuns market CNBC
11:56AM  A tattoo may end fingerpricks for diabetics at CNBC
07:28AM  U.S.-listed stocks of Swiss companies get a lift as franc soars at MarketWatch
06:42AM  European Stocks Trade Mixed After Switzerland Scraps Euro Exchange Cap at TheStreet
Jan-14-15 06:20PM  Roche to Acquire Up to 56% Interest in Foundation Medicine - Analyst Blog Zacks
06:05PM  ARIAD Reveals 2015 Strategic Objectives, Updates on Pipeline - Analyst Blog Zacks
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company's Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerSep 22Buy15.00325,0004,875,0004,644,328Sep 24 05:42 PM